SCHEMBL6096495

SCHEMBL6096495

COC1=C(OC)C(=O)C(Cc2ccc(OCc3cccnc3)c(C(=O)N3CCC(C)CC3)c2)=C(C)C1=O

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 2/20 0.40
HTT P42858 2/20 0.40
MAPT P10636 1/20 0.40
RAB9A P51151 1/20 0.40
CSF1R P07333 1/20 0.39
GPR132 Q9UNW8 1/20 0.38
MGLL Q99685 1/20 0.37
PDE3B Q13370 2/20 0.37
PDE3A Q14432 2/20 0.37
TBXAS1 P24557 1/20 0.37
LRRK2 Q5S007 1/20 0.37
ALDH1A1 P00352 2/20 0.37
HPGD P15428 2/20 0.37
HSD17B10 Q99714 1/20 0.37
KDM1A O60341 1/20 0.37
TRPM5 Q9NZQ8 1/20 0.36
CYP1A2 P05177 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2D6 P10635 1/20 0.36
CYP2C9 P11712 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6094504 0.91 NPC1 (0.41) NPC1RAB9ACSF1RPDE3BPDE3A
SCHEMBL6096031 0.90 P2RY12 (0.45) NPC1RAB9APDE3BPDE3AALDH1A1
SCHEMBL6097833 0.84 LRRK2 (0.45) TBXAS1LRRK2HSD17B10
SCHEMBL6095130 0.83 LRRK2 (0.44) TBXAS1LRRK2ALDH1A1CYP1A2CYP3A4
SCHEMBL6094905 0.82 SCN9A (0.42) NPC1HTTMAPTRAB9ACSF1R
SCHEMBL6095995 0.81 POLB (0.44) HTTALDH1A1HSD17B10
SCHEMBL6095925 0.81 SGMS2 (0.46) HTTRAB9ALRRK2ALDH1A1
SCHEMBL6095437 0.81 SCN9A (0.48) NPC1MAPTRAB9AALDH1A1HPGD
SCHEMBL6095213 0.80 HSD17B10 (0.42) NPC1HTTMAPTRAB9ACSF1R
SCHEMBL6094786 0.79 LRRK2 (0.61) LRRK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7064124-B2 NF-κB inhibitor containing substituted benzoic acid derivative as active ingredient DAIICHI SUNTORY PHARMA CO., LTD. (JP) 2006-06-20 US claimed
US-7064124-B2 NF-κB inhibitor containing substituted benzoic acid derivative as active ingredient DAIICHI SUNTORY PHARMA CO., LTD. (JP) 2006-06-20 US disclosed
US-20040122244-A1 Nf-kappa b inhibitor containing substituted benzoic acid derivative as active ingredient DAIICHI ASUBIO PHARMA CO., LTD. (JP) 2004-06-24 US disclosed
EP-1314712-A1 NF-KAPPA-B INHIBITOR CONTAINING SUBSTITUTED BENZOIC ACID DERIVATIVE AS ACTIVE INGREDIENT Daiichi Suntory Pharma Co., Ltd. (JP) 2003-05-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040122244-A1 Nf-kappa b inhibitor containing substituted benzoic acid derivative as active ingredient NFKBIA, NFKB1, IKBKB NPC1 1501/4885HTT 3970/4885MAPT 2457/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.